Epiphany Announces Positive Results From Its Phase 2b Trial In Shingles Epiphany Announces Positive Results From Its Phase 2b Trial In Shingles

Health News

Health Videos

Forum

Advertise

Seniors / Aging News

Useful Links

Video Library

Epiphany Announces Positive Results From Its Phase 2b Trial In Shingles Main Category: Seniors / Aging

Also Included In: Infectious Diseases / Bacteria / Viruses; Clinical Trials / Drug Trials; Pharma Industry / Biotech Industry

Article Date: 19 Nov 2009 - 3:00 PST

email to a friend printer friendly view / write opinions rate article

Current Article Ratings:

Patient / Public:

Health Professional:

Article Opinions: 0 posts

Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash. The double-blinded study enrolled 373 patients, randomized into 3 arms: 1 gram of once-daily EPB-348, 2 grams of once-daily EPB-348, thrice-daily valacyclovir (1 gram, three times per day). Eighteen patients also received 3 grams of once-daily EPB-348.

Once-daily EPB-348 at two grams met its primary endpoint of non-inferiority to valacyclovir. Valomaciclovir (EPB-348) was also non-inferior to valacyclovir in the secondary endpoints of time to complete pain resolution, time to rash resolution and time to cessation of new lesion formation. The highest dose of valomaciclovir (3 grams once daily) demonstrated superiority to valacyclovir with regards to the primary endpoint (p-value { 0.007).

Dose-dependent trends to improved pain resolution in the subset of treated patients who were over 50 years old and trends to faster resolution of severe pain in patients of all ages were seen in the higher dose EPB-348 treatment arms when compared to valacyclovir. All doses of EPB-348 showed improvement over valacyclovir for patients presenting for first treatment towards the end of the 72 hour treatment window. Currently-approved shingles treatments are effective only within the first 72 hours of rash appearance.

"These Phase 2 data indicate that once-daily valomaciclovir could be more convenient than three times daily valacyclovir for the treatment of herpes zoster, and it is equally safe. Moreover, the 3 gram dose of valomaciclovir was superior to valacyclovir in terms of clinical efficacy. Therefore, Phase 3 studies with larger numbers of patients are clearly indicated," said Stephen Tyring, MD, PhD, Clinical Professor at the University of Texas Health Sciences Center, the lead investigator of the study.

There were no differences in significant adverse events between valomaciclovir and valacyclovir groups. The most common adverse event in all patient groups was nausea. No patient discontinued treatment due to adverse events related to EPB-348 use.

"We are pleased with our Phase 2b results that demonstrate once-daily EPB-348 is both safe and active in treating shingles. We are encouraged by the trends to better pain resolution and less severe pain in the valomaciclovir-treated patients. We anticipate that EPB-348 may be the first once-a-day shingles drug with a wider treatment window and a reduction in both the incidence and severity of shingles associated pain. We look forward to demonstrating these and other additional benefits in Phase 3 clinical trials," said Fred Volinsky, MD, Epiphany Biosciences' CEO.

EPB-348 has also been shown to be effective against acute infectious mononucleosis, for which there is no FDA-approved treatment, in a Phase 2a study. Data from this study were presented during the 2009 ICAAC meeting in San Francisco.

About EPB-348

EPB-348 is a potent inhibitor of herpes viruses, including the varicella zoster and Epstein-Barr viruses. It has been studied clinically in both shingles and infectious mononucleosis.

About Shingles

Shingles is a reactivation of the varicella zoster virus, the same virus that causes chickenpox in children, and infects over 90% of the US adult population. An estimated 5 in 1000 people suffer from shingles in the US every year, and 20% of all individuals are estimated to experience at least one episode of shingles during their lifetime. The risk of shingles outbreak dramatically increases with age.

Shingles manifests itself as a painful rash that develop into blisters, often mainly on one side of the body. The normal healing process takes about four weeks. Shingles pain is frequently observed as zoster associated pain (ZAP) and post-herpetic neuralgia (PHN). ZAP is present during the initial disease outbreak. PHN is a persistent pain that is present in some patients long after the lesions have resolved.

About Epiphany Biosciences

Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella zoster virus (VZV), Epstein-Barr Virus (EBV) and hepatitis C virus (HCV).

Source: Epiphany Biosciences, Inc

Please rate this article:

(Hover over the stars

then click to rate) Patient / Public:

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Back to top Back to front page List of All Medical Articles

News Category Menu

* Seniors / Aging

* Women's Health

* View full category list

News OptionsPersonalized Homepage Weekly Newsletters Daily News Alerts

What Is... Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Conditions Information

Health Professional SitesOphthalmology Urology

Clinical Trials

- Map Of H1N1 Outbreaks

- Swine Flu - Top 20 FAQ

- Daily Email News Alerts

Stick with Medical News Today for the latest news updates on swine flu.

Latest News For Seniors / Aging

Epiphany Announces Positive Results From Its Phase 2b Trial In Shingles

19 Nov 2009

Scientists Find Molecular Trigger That Helps Prevent Aging And Disease

19 Nov 2009

Collaboration With University Of Washington Aims To Prevent Dementia, Including Alzheimer's

19 Nov 2009

View more news...

Most Popular Articles For Seniors

These are the most read articles from this news category for the last 6 months:

Testosterone Replacement For Men With Low Testosterone Improves Liver Function, Metabolic Syndrome

13 Jun 2009

In middle-aged and older men with low testosterone levels, long-term testosterone replacement therapy greatly improves their fatty liver disease and their risk factors for cardiovascular disease and diabetes, a new study found...

What Is Shingles? What Causes Shingles?

23 Jun 2009

What Is Alzheimer's Disease? What Causes Alzheimer's Disease?

31 Jul 2009

20 Oct 2009

Latest Videos for Seniors

Keeping a Personal Medical Record

Medical information is usually scattered in many different places. To receive the best possible health care, people are encouraged to gather information in one place and create a personal medical record...

Cholesterol Management

Each year more than a million Americans have heart attacks. High cholesterol can form a blockage in the arteries and lead to heart disease. Lifestyle changes and adherence to a treatment plan are important for cholesterol management...

View more videos...

Most Popular Categories

swine flu nutrition cancer cardiovascular diabetes hiv obesity pediatrics neurology dermatology urology pregnancy psychology medicare infectious diseases alcohol breast cancer women's health asthma gastrointestinal alzheimer's stem cell research prostate bones pain sexual health smoking eye health sleep sports medicine multiple sclerosis health insurance medical devices hypertension dentistry biology genetics depression it arthritis autism pharma industry fertility abortion liver disease mrsa seniors nursing anxiety allergy

concept		evidence	hits	links
	$drug_related [news] [concept]	$illegal_drugs
	$drugwar_propaganda 70% [news] [concept]	$propaganda_theme2 $propaganda_theme3 $propaganda_theme5		Classic Modern Drug Propaganda Themes in Chemical Prohibition Drug War Propaganda (book)
	$propaganda_theme2 70% [news] [concept]	"Anxiety" "Alzheimer's Disease" "heart attacks" "Cancer" "depression"	11	Madness,Crime,Violence,Illness (propaganda theme 2) http://www.drugwarfacts.org/crime.htm http://www.drugwarfacts.org/causes.htm Distortion 18: Cannabis and Mental Illness
	$propaganda_theme3 50% [news] [concept]	"Americans"	1	Survival of Society (propaganda theme 3)
	$propaganda_theme5 60% [news] [concept]	"children"	1	Children Corrupted (propaganda theme 5) http://www.drugwarfacts.org/adolesce.htm
	$illegal_drugs [news] [concept]	$narcotic
	$drugs 90% [news] [concept]	$various_drugs
	$chemicals 50% [news] [concept]	$alcohol		http://www.erowid.org/chemicals/chemicals.s...
	$opioid [news] [concept]	"Opioid"	1	Managing Pain
	$depressant_intoxicant 50% [news] [concept]	$alcohol
	$narcotic [news] [concept]	$opioid		Managing Pain
	$alcohol 50% [news] [concept]	"alcohol"	1	Stanton Peele Addiction Web Site http://www.drugwarfacts.org/alcohol.htm
	$various_drugs 90% [news] [concept]	"Drug"	2
	$religious_use 50% [news] [concept]	"Epiphany"	9	http://www.erowid.org/entheogens/spiritual.... http://en.wikipedia.org/wiki/Religion_and_d... http://www.csp.org/ Cannabis: Religious and Spiritual Uses http://www.mapinc.org/spirit.htm
	$youth 60% [news] [concept]	$propaganda_theme5		http://www.ssdp.org/ http://www.mapinc.org/youth.htm
	$school [news] [concept]	"University"	2	http://www.ssdp.org/

observer's propaganda picks

See drug-warrior propaganda somewhere?
Submit text or a url, and bot will analyze prohibition propaganda for you!

Prohibition-era cartoons
Anti-prohibition political cartoons from Prohibition I.

Donate to drugsense please give generously!